Clinical Trials
16 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06959641 2026-05-22
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT04759911 2026-05-20
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07376837 2026-05-19
PTC-RFA
University Health Network, Toronto
Phase NA Recruiting
NCT01398085 2026-05-07
IoN
University College, London
Phase 2/3 Active not recruiting
NCT06899347 2026-05-05
PRO-COMAND
University of Pisa
Phase NA Not yet recruiting
NCT07545837 2026-04-27
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
Mayo Clinic
Phase NA Not yet recruiting
NCT07536412 2026-04-17
Decision Aid Efficacy in Low Risk Thyroid Cancer
University of Maryland, Baltimore
Phase NA Not yet recruiting
NCT01709292 2026-04-16
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07529080 2026-04-14
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03914300 2026-04-13
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07521670 2026-04-13
STRAP
National Cancer Centre, Singapore
Phase 2 Not yet recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated